semaglutide cardiovascular outcomes news 2025 october A Lancet analysis of the SELECT trial concluded that reduced major adverse events by 20% in adults with overweight or obesity, regardless of how much weight patients actually lost Semaglutide and cardiovascular outcomes by

A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo

Furthermore, the difference in efficacy of weight reduction between the 2 agents may become even greater with more prolonged use of teratrutide beyond 48 weeks

We prescribe PT-141 because we understand the difference

Although stopping Ozempic and weight gain are certainly related to one another, those who choose to gradually lower the doses will be much less likely to experience any serious withdrawal symptoms

This can help ensure safe treatment

Contamination happens easily and ruins entire vials